Dermoskeletons to preserve mobility and function in inclusion body myositis

Océane Landon-Cardinal, MD, François Prince, PhD, Stéphane Bédard, PEng, MSc, Olivier Benveniste, MD, PhD, and Marie Hudson, MD, MPH

Neurology® 2018;91:760. doi:10.1212/WNL.0000000000006365

Correspondence

Dr. Landon-Cardinal
o.landoncardinal@gmail.com

MORE ONLINE

Video

A 45-year-old man developed gradual onset of finger flexors and quadriceps weakness. Anti-NTSC1A antibody was positive, and muscle biopsy was consistent with inclusion body myositis. Options to preserve his mobility were explored. The Dermoskeleton uses high-end sensors and advanced artificial intelligence to detect the user's mobility intentions and generate synchronized assistance at the motorized knees. The device considerably improved the patient's 6-minute walk test (720–790 m) and stair climbing capacity (69–140 steps per minute) (videos 1 and 2), as a result of both assistance (primary) and bracing (secondary) factors. Advancing biomechanical technology provides novel options to preserve mobility and function for patients with neuromuscular diseases.

Author contributions

O. Landon-Cardinal, F. Prince, S. Bédard, and M. Hudson: conceptualization and design. O. Landon-Cardinal, F. Prince, and M. Hudson: acquisition of data. O. Landon-Cardinal, F. Prince, O. Benveniste, and M. Hudson: analysis and interpretation of data. O. Landon-Cardinal, F. Prince, S. Bédard, O. Benveniste, and M. Hudson: critical revision of the manuscript for important intellectual content.

Acknowledgment

The authors specially thank the PERFORM Centre, Concordia University, for providing the ideal spaces for shooting these videos and for providing an ideal research environment.

Study funding

No targeted funding reported.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

From the Hôpital Pitié-Salpêtrière (O.L.-C., O.B.), AP-HP, Department of Internal Medicine and Clinical Immunology, Inflammation-Immunopathology-Biotherapy Department (I2B), East Paris Neuromuscular Diseases Reference Center, Inserm U974, France; Departments of Kinesiology and Surgery (F.P.), University of Montreal, B-Temia Inc. (S.B.), Québec City, and Division of Rheumatology (M.H.), Department of Medicine, Jewish General Hospital, Lady Davis Institute, Montréal, Québec, Canada.

Neurology®

Dermoskeletalics to preserve mobility and function in inclusion body myositis

Océane Landon-Cardinal, François Prince, Stéphane Bédard, et al.

Neurology 2018;91;760

DOI 10.1212/WNL.0000000000006365

This information is current as of October 15, 2018

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/91/16/760.full
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Neuromuscular Disease http://n.neurology.org/cgi/collection/all_neuromuscular_disease Autoimmune diseases http://n.neurology.org/cgi/collection/autoimmune_diseases Muscle disease http://n.neurology.org/cgi/collection/muscle_disease
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2018 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.